CRESCENT BIOPHARMA, INC.CBIOEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Crescent Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing and commercializing novel targeted therapies to address unmet medical needs, focusing primarily on the rare disease, oncology and immunology treatment segments, serving patients across North America and key global markets.
CBIO Q3 FY2022 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-8.8M
Net Profit
$-8.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.16
CRESCENT BIOPHARMA, INC. Q3 FY2022 Financial Summary
CRESCENT BIOPHARMA, INC. reported revenue of $0 for Q3 FY2022, with a net profit of $-8.5M (up 50.8% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-8.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2022 |
CRESCENT BIOPHARMA, INC. Quarterly Revenue & Net Profit History
CRESCENT BIOPHARMA, INC. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2022 | $0 | — | $-8.5M | N/A |
| Q2 FY2022 | $75.0K | +52716.9% | $-13.3M | -17690.1% |
Income Statement
| Q2 2022 | Q3 2022 | |
|---|---|---|
| Revenue | $75000 | $0 |
| YoY Growth | 52716.9% | N/A |
Balance Sheet
| Q2 2022 | Q3 2022 | |
|---|---|---|
| Assets | $65.0M | $56.0M |
| Liabilities | $9.3M | $7.8M |
| Equity | $55.7M | $48.1M |
Cash Flow
| Q2 2022 | Q3 2022 | |
|---|---|---|
| Operating CF | $-16.2M | $-8.6M |